20 74

Cited 0 times in

Association of metformin use with Alzheimer's disease in patients with newly diagnosed type 2 diabetes: a population-based nested case-control study

Authors
 Junghee Ha  ;  Dong-Woo Choi  ;  Kwang Joon Kim  ;  So Yeon Cho  ;  Hyunjeong Kim  ;  Keun You Kim  ;  Youngseung Koh  ;  Chung Mo Nam  ;  Eosu Kim 
Citation
 SCIENTIFIC REPORTS, Vol.11(1) : 24069, 2021-12 
Journal Title
SCIENTIFIC REPORTS
Issue Date
2021-12
MeSH
Aged ; Aged, 80 and over ; Alzheimer Disease / epidemiology* ; Alzheimer Disease / etiology* ; Biomarkers ; Case-Control Studies ; Comorbidity ; Diabetes Mellitus, Type 2 / complications* ; Diabetes Mellitus, Type 2 / drug therapy ; Diabetes Mellitus, Type 2 / epidemiology* ; Disease Susceptibility ; Female ; Humans ; Hypoglycemic Agents / adverse effects* ; Hypoglycemic Agents / therapeutic use ; Male ; Metformin / adverse effects* ; Metformin / therapeutic use ; Population Surveillance ; Risk Assessment ; Risk Factors
Abstract
Metformin reduces insulin resistance, which constitutes a pathophysiological connection of diabetes with Alzheimer's disease (AD), but the evidence of metformin on AD development was still insufficient and conflicting. We investigated AD risk in patients with newly diagnosed type 2 DM treated with metformin. This retrospective, observational, nested case-control study included patients with newly diagnosed type 2 DM obtained from the Korean National Health Insurance Service DM cohort (2002-2017). Among 70,499 dementia-free DM patients, 1675 AD cases were matched to 8375 controls for age, sex, and DM onset and duration. The association between AD and metformin was analyzed by multivariable regression analyses, adjusted for comorbidities and cardiometabolic risk profile. Metformin use was associated with an increased odds of AD (adjusted odds ratio [AOR] 1.50; 95% CI 1.23-1.83). The risk of AD was higher in patients with a longer DM duration. Furthermore, AD risk was significantly high in DM patients with depression (AOR 2.05; 95% CI 1.02-4.12). Given the large number of patients with DM who are taking metformin worldwide, a double-blinded, prospective study is required to determine the long-term cognitive safety of metformin.
Files in This Item:
T202125566.pdf Download
DOI
10.1038/s41598-021-03406-5
Appears in Collections:
1. College of Medicine (의과대학) > Research Institute (부설연구소) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Preventive Medicine (예방의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Psychiatry (정신과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Kwang Joon(김광준) ORCID logo https://orcid.org/0000-0002-5554-8255
Kim, Keun You(김근유) ORCID logo https://orcid.org/0000-0001-7192-2828
Kim, Eosu(김어수) ORCID logo https://orcid.org/0000-0001-9472-9465
Kim, Hyun Jeong(김현정)
Nam, Chung Mo(남정모) ORCID logo https://orcid.org/0000-0003-0985-0928
Ha, Junghee(하정희) ORCID logo https://orcid.org/0000-0002-4217-3570
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/188130
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links